Document:

EX-10.2

 Exhibit 10.2 

GOODRICH PETROLEUM 

AMENDED AND RESTATED 

OFFICER SEVERANCE PLAN 
 (As
Amended and Restated August 22, 2018) 
 The Goodrich Petroleum Amended and Restated Officer Severance Plan (as amended from time to
time, the “Plan”) is amended and restated effective as of August 22, 2018 (the “Effective Date”), pursuant to the authorization of the Board of Directors (“Board”) of Goodrich Petroleum Corporation (the
“Company”), to provide financial security to Covered Executives in the event of an involuntary termination of employment. 
 The
Plan as set forth herein constitutes an amendment and restatement of the Goodrich Petroleum Officer Severance Plan originally adopted by Goodrich Petroleum Company, L.L.C. (“GPC LLC”) effective as of December 12, 2006 and amended and
restated effective as of December 31, 2010. 
 I. 

DEFINITIONS AND CONSTRUCTION 

1.1    Definitions. Where the following words and phrases appear in the Plan, they shall have the respective
meanings set forth below, unless their context clearly indicates to the contrary. 
 “Annual Base Salary” shall mean the
highest annual rate of base salary of a Covered Executive in effect during the six-month period ending immediately prior to (i) a Change of Control (if one has occurred) or (ii) the Covered Executive’s Involuntary Termination,
whichever results in the greater amount. 
 “Board” shall mean the board of directors or managers, as the case may be, of
the Company or its successor. 
 “Bonus Amount” shall mean the annual cash bonus last awarded to the Covered Executive for
the preceding fiscal year or, if greater (and applicable), the annual cash bonus awarded to the Covered Executive for the fiscal year immediately prior to the fiscal year in which a Change of Control occurs. 

“Cause” shall mean any termination of a Covered Executive’s employment by the Employer by reason of the Covered
Executive’s: (1) willful and continued failure to perform substantially the Covered Executive’s duties (other than any such failure resulting from the Covered Executive’s incapacity due to a physical or mental illness) after
written notice of such failure has been given to the Covered Executive by the Committee specifying in detail such failure and the Covered Executive has had a reasonable period (not to exceed 30 days) to correct such failure; (2) conviction (or
plea of nolo contendere) for any felony or any other crime which involves moral turpitude; or (3) gross negligence or willful misconduct in the performance of the Covered Executive’s duties; provided, however, that no act or failure to act
on the part of the Covered Executive shall be considered “gross negligence” or “willful misconduct” if done or omitted to be done by the Covered Executive in good faith and in the reasonable belief that such act or failure to act
was in the best interest of the Employer or its affiliates. 

 “Change in Duties” shall mean the occurrence, on or within 18 months after
the date upon which a Change of Control occurs, of any one or more of the following: 
 (1)    a material reduction in
the duties or responsibilities of a Covered Executive from those applicable to him immediately prior to the date on which the Change of Control occurs; 

(2)    a material reduction in a Covered Executive’s annual rate of base salary in effect immediately prior to the
Change of Control; or 
 (3)    a change in the location of a Covered Executive’s principal place of employment by
more than 50 miles from the location where he was principally employed immediately prior to the date on which the Change of Control occurs, unless such relocation is agreed to in writing by the Covered Executive; provided, however, that a relocation
scheduled prior to the date of the Change of Control shall not constitute a Change in Duties. 
 “Change of Control” shall
mean the occurrence of any of the following events: 
 (1)    the consummation of any transaction (including, without
limitation, any merger, consolidation, tender offer, or exchange offer) the result of which is that any individual, entity, group or “person” (as such term is used in Sections 13(d)(3) and 14(d)(2), of the Securities Exchange Act of 1934
(the “Exchange Act”)), other than the Company, a subsidiary thereof or an employee benefit plan of either, becomes the “beneficial owner” (as such term is defined in Rule 13d-3 and Rule 13d-5 under the Exchange Act), directly or indirectly, of stock and/or securities representing 50% or more of the combined voting power of the then outstanding voting securities of the Company, 

(2)    a change in the composition of the Board of Directors of the Company, as a result of which fewer than a majority of
the non-executive directors are Incumbent Directors. “Incumbent Directors” shall mean non-executive directors who either (A) are non-executive directors as of December 31, 2010, or (B) are elected, or nominated for election, thereafter to the Board of Directors of the Company with the affirmative votes of at least a majority of the
Incumbent Directors at the time of such election or nomination, but “Incumbent Director” shall not include an individual whose election or nomination is in connection with (i) an actual or threatened election contest (as such terms
are used in Rule 14a-11 of Regulation 14A promulgated under the Securities Exchange Act of 1934) or an actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Board
or (ii) a plan or agreement to replace a majority of the then Incumbent Directors, 
 (3)    the consummation of
the sale, lease, transfer, conveyance or other disposition (including by merger or consolidation) in one or a series of related transactions, of all or substantially all of the assets of the Company and its subsidiaries, taken as a whole (other than
to an entity wholly owned, directly or indirectly, by the Company), unless, following such transaction, all or substantially all of the persons who were the beneficial owners of the outstanding voting stock and securities of the Company immediately
prior to such transaction beneficially own, directly or indirectly, more than 60% of, respectively, the then outstanding voting stock and securities of the entity resulting from such transaction in substantially the same proportions as immediately
prior to such transaction, or 

  
 -2- 

 (4)    the adoption of a plan relating to the liquidation or dissolution
of the Company. 
 Notwithstanding the foregoing, a Change of Control must also be a “change of control” as defined in Section 409A of the
Code and the applicable Treasury Regulations promulgated thereunder. 
 “Code” shall mean the Internal Revenue Code of
1986, as amended. 
 “Committee” shall mean the Board; however, the Board may delegate all or part of its authority under
the Plan to the Board of Directors of the Company or to any executive of the Company , GPC LLC or any other Employer, as it may choose. 

“Covered Executive” shall mean an executive who (i) is a senior vice president or a vice president of an Employer, and
(ii) does not have a written employment or severance agreement with the Employer. For purposes of this Plan, any adverse change in a Covered Executive’s status as being a senior vice president or vice president of an Employer that occurs
within six months prior to his Involuntary Termination shall be disregarded. 
 “Employer” shall mean the Company, GPC LLC
and each eligible entity designated as an Employer in accordance with the provisions of Section 4.4 of the Plan. 

“ERISA” shall mean the Employee Retirement Income Security Act of 1974, as amended. 

“Executive Officer” shall mean an “officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, provided such individual has been appointed by the Board accordingly.  

“Health Benefit Coverages” shall mean coverage under each group health plan sponsored or contributed to by an Employer for
its similarly situated active executives. 
 “Involuntary Termination” shall mean any termination of the Covered
Executive’s employment with the Employer that results from either: 
 (1)    a termination (whether before, on or
following a Change of Control) by the Employer other than for Cause; or 
 (2)    a Qualified Termination by the Covered
Executive on or within 18 months following a Change of Control; 
 provided, however, that the term ‘Involuntary Termination’ shall not
include: (i) a termination by the Employer for Cause; (ii) any termination as a result of the Covered Executive’s death or a disability under circumstances entitling him to disability benefits under the standard long-term disability
plan of the Employer; (iii) any termination as a result of the Covered Executive declining to accept an offer of comparable employment from a successor employer; or (iv) any 

  
 -3- 

 
voluntary resignation or retirement by the Covered Executive. For purposes of clause (iii), “comparable employment” shall mean employment that would not result in a Change in Duties for
the Covered Executive. 
 “Qualified Termination” shall mean that, within 60 days of the Covered Executive receiving notice
of, or learning of, a Change in Duties, the Covered Executive gives written notice of such Change in Duties to the Committee and the Employer fails to remedy such Change in Duties within 30 days of the Committee’s receipt of the notice thereof
from the Covered Executive. If the Employer fails to remedy the Change in Duties event during such 30-day “cure” period, the Covered Executive’s employment shall terminate due to a Change in
Duties immediately following the end of the 30-day “cure” period. If the Employer remedies the Change in Duties event within such 30-day period, then the event
giving rise to the Covered Executive’s notice shall not constitute a Change in Duties and the Covered Executive’s employment shall continue. 

“Release” shall mean a general release, substantially in the form attached hereto, from the Covered Executive that releases
the Company and its affiliates from employment-related claims. 
 “Vesting Continuation Period” shall mean, as applicable,
(i) if a Covered Executive who is an Executive Officer experiences an Involuntary Termination on or before December 31, 2018, the period beginning on the date of the Involuntary Termination and ending on December 31, 2019 or
(ii) if a Covered Executive who is an Executive Officer experiences an Involuntary Termination after December 31, 2018, the period beginning on the date of the Involuntary Termination and ending on the date that is 12 months following the
date of the Involuntary Termination. 
 1.2    Number and Gender. Wherever appropriate herein,
words used in the singular shall be considered to include the plural and the plural to include the singular. The masculine gender, where appearing in this Plan, shall be deemed to include the feminine gender. 

1.3    Headings. The headings of Articles and Sections herein are included solely for convenience and if
there is any conflict between such headings and the text of the Plan, the text will control. 
 II. 

SEVERANCE BENEFITS 

2.1    Post Change of Control Severance Payments. Subject to the further provisions of (i) this Article
II, including Section 2.3, and (ii) Sections 4.10 and 4.12, if a Covered Executive incurs an Involuntary Termination on or within 18 months following a Change of Control, then, as soon as practical following his Release becoming
irrevocable, but not later than 10 days after such date, such Covered Executive shall be entitled to the following severance benefits: 

(a)    a lump sum cash payment equal to (i) if the Covered Executive is an Executive Officer or a senior vice
president of an Employer, two times the sum of his Annual 

  
 -4- 

 
Base Salary and Bonus Amount, or (ii) if the Covered Executive is a vice president of an Employer but is not an Executive Officer, the sum of his Annual Base Salary and Bonus Amount; 

(b)    if, following his Involuntary Termination, the Covered Executive timely elects COBRA continuation coverage for the
Covered Executive and, where applicable, his eligible dependents, his monthly premium for such COBRA coverage, for up to 18 months (or, in the case of a Covered Executive who is an Executive Officer, 24 months), shall be equal to the active employee
monthly premium charged for similar Health Benefit Coverage (the “Subsidized COBRA Coverage”). However, if such Subsidized COBRA Coverage for the Covered Executive would result in his coverage, or the benefits received under the health
benefit plan, being taxable to the Covered Executive, the Employer shall take all actions necessary to make the Covered Executive “whole” on an after-tax basis for any such adverse tax consequences.
If at any time on or after the Covered Executive’s Involuntary Termination any health benefit plan in which he is continuing his coverage pursuant to this Section 2.1(b) either is terminated or ceases to provide coverage to him or his
covered beneficiaries for any reason, other than as provided below, prior to the end of the period of Subsidized COBRA Coverage, then the Employer shall pay the Covered Executive timely an amount of cash necessary for the Covered Executive to obtain
for the period of Subsidized COBRA Coverage then remaining substitute coverage that is substantially equivalent to the coverage that was provided to the Covered Executive before such termination, plus, if applicable, a
gross-up payment to reflect the loss of any tax benefits associated with his “loss” of employer-provided health plan coverage benefit(s). Notwithstanding the foregoing, the period of Subsidized COBRA
Coverage shall immediately terminate upon the Covered Executive’s obtainment of new employment and his eligibility for group health plan coverage from his new employer (with the Covered Executive being obligated hereunder to promptly report
such eligibility to the Employer); and 
 (c)    a lump sum cash payment equal to the sum of (i) his earned, but
unpaid, annual base salary up to the date of his Involuntary Termination and (ii) any accrued, but untaken, vacation time or paid-time off. 

2.2    Pre-Change of Control Severance Payments. Subject to the
further provisions of (i) this Article II, including Section 2.3, and (ii) Sections 4.10 and 4.12, if a Covered Executive incurs an Involuntary Termination prior to a Change of Control, then, as soon as practical following his Release
becoming irrevocable, but not later than 10 days after such date, such Covered Executive shall be entitled to the following severance benefits: 

(a)    a lump sum cash payment equal to (i) if the Covered Executive is an Executive Officer or a senior vice
president of an Employer, two times the sum of his Annual Base Salary and Bonus Amount, or (ii) if the Covered Executive is a vice president of an Employer but is not an Executive Officer, 50% of the sum of his Annual Base Salary and Target
Bonus Amount; 
 (b)    if, following his Involuntary Termination, the Covered Executive timely elects COBRA
continuation coverage for the Covered Executive and, where applicable, his eligible dependents, his monthly premium for such COBRA coverage, for up to six months (or, in the case of a Covered Executive who is an Executive Officer, 24 months), shall
be equal to the 

  
 -5- 

 
Subsidized COBRA Coverage. However, if such Subsidized COBRA Coverage for the Covered Executive would result in his coverage, or the benefits received under the health benefit plan, being taxable
to the Covered Executive, the Employer shall take all actions necessary to make the Covered Executive “whole” on an after-tax basis for any such adverse tax consequences. If at any time on or after
the Covered Executive’s Involuntary Termination any health benefit plan in which he is continuing his coverage pursuant to this Section 2.2(b) either is terminated or ceases to provide coverage to him or his covered beneficiaries for any
reason, other than as provided below, prior to the end of the period of Subsidized COBRA Coverage, then the Employer shall pay the Covered Executive timely an amount of cash necessary for the Covered Executive to obtain for the period of Subsidized
COBRA Coverage then remaining substitute coverage that is substantially equivalent to the coverage that was provided to the Covered Executive before such termination, plus, if applicable, a gross-up payment to
reflect the loss of any tax benefits associated with his “loss” of employer-provided health plan coverage benefit(s). Notwithstanding the foregoing, the period of Subsidized COBRA Coverage shall immediately terminate upon the Covered
Executive’s obtainment of new employment and his eligibility for group health plan coverage from his new employer (with the Covered Executive being obligated hereunder to promptly report such eligibility to the Employer); and 

(c)    a lump sum cash payment equal to the sum of (i) his earned, but unpaid, annual base salary up to the date of
his Involuntary Termination and (ii) any accrued, but untaken, vacation time or paid-time off. 

2.3    Treatment of Equity Awards. 

(a)    Subject to (i) the further provisions of this Article II, including Section 2.3, and (ii) compliance
with the non-competition and non-solicitation covenants attached hereto as Exhibit A, if a Covered Executive who is an Executive Officer incurs an Involuntary
Termination prior to a Change of Control, (A) the portion of any unvested and unearned restricted stock (or restricted stock unit) awards held by the Covered Executive vesting solely pursuant to the passage of time and continued services and
granted pursuant to the Company’s Management Incentive Plan (or other equity compensation plan) (the “Restricted Stock”) that would, but for the Covered Executive’s termination, vest during the Vesting Continuation Period
will immediately vest on the date of the Involuntary Termination, and (B) any unearned performance awards held by the Covered Executive to be settled in common stock of the Company, conditioned upon the achievement of performance targets and
granted pursuant to the Company’s Management Incentive Plan (or other equity compensation plan) (the “Performance Shares”) will (1) be prorated by multiplying the number of Performance Shares by a fraction (no greater than
one) the numerator of which is the number of months in the period beginning on the date of grant of the Performance Shares and ending on last day of the Vesting Continuation Period and the denominator of which is the number of months in the
performance period under the Performance Shares (with the remainder of the Performance Shares being immediately forfeited to the Company for no consideration upon the Covered Executive’s termination of employment) and (2) such reduced
award will vest, if at all, based on the achievement of the performance goals set forth in each outstanding Performance Share award utilizing a shortened performance period under the award ending on the date of the Involuntary Termination; provided,
however, that the preceding sentence is not intended to modify the vesting provisions applicable to either the “Grant of Restricted Stock (Secondary Exit Award; UCC Warrant Exercise)” or the “Grant of Restricted Stock (Secondary Exit
Award: 2L Note Conversion)” (together the “Emergence Awards”). 

  
 -6- 

 (b)    Notwithstanding Section 2.3(a), subject to (i) the
further provisions of this Article II, including Section 2.3, and (ii) compliance with the non-competition and non-solicitation covenants attached hereto as
Exhibit A, if a Covered Executive who is an Executive Officer incurs an Involuntary Termination on or within 18 months following a Change of Control, any unvested and unearned Restricted Stock held by the Covered Executive will immediately
vest in full. Nothing contained in this Section 2.3(b) is intended to modify the vesting provisions applicable to the Emergence Awards. 

(c)    Notwithstanding anything contained herein to the contrary, upon a Change of Control, any unearned Performance
Shares held by a Covered Executive who is an Executive Officer will immediately vest, if at all, based on the achievement of the performance goals set forth in each outstanding Performance Share award utilizing a shortened performance period under
the award ending on the date of the Change of Control. Nothing contained in this Section 2.3(c) is intended to modify the vesting provisions applicable to the Emergence Awards. 

(d)    If the employment of a Covered Executive who is an Executive Officer is terminated for any reason or no reason
prior to the vesting of the Emergence Awards they will be automatically forfeited to the Company for no consideration upon such termination. In the event a Covered Executive violates any of the terms of the
non-competition and non-solicitation covenants set forth on Exhibit A, the Covered Executive will automatically forfeit to the Company for no consideration all
outstanding unvested equity and equity-based compensation awards related to the common stock of the Company. After giving effect to any accelerated or continued vesting pursuant to the foregoing provisions of this Section 2.3, any outstanding
unvested equity and equity-based compensation awards related to the common stock of the Company (which awards did not vest pursuant to the foregoing provisions of this Section 2.3) will immediately be forfeited to the Company for no
consideration. 
 (e)    Notwithstanding the terms of any outstanding agreements evidencing Restricted Stock or
Performance Shares, (1) if the employment of a Covered Executive who is an Executive Officer is terminated for any reason other than pursuant to a Involuntary Termination prior to the vesting of the Restricted Stock or Performance Shares, the
Restricted Stock and Performance Shares will be forfeited to the Company for no consideration upon such termination, and (2) Section 3(c) of all outstanding agreements evidencing Restricted Stock or Performance Shares is hereby deleted
such that the occurrence of a Change of Control (as defined in the Company’s Management Incentive Plan) will not automatically result in accelerated vesting of the Covered Executive’s Restricted Stock or Performance Shares or the
shortening of the performance period under the Covered Executive’s Performance Shares. This Section 2.3 is intended to amend the outstanding Restricted Stock and Performance Share agreements for each Covered Executive who is an Executive
Officer to modify, in the manner described in the foregoing provisions of this Section 2.3, the provision of accelerated vesting with respect to the Covered Executive’s outstanding Restricted Stock and Performance Shares and such
additional agreements are hereby deemed amended without the need to execute any further documents. 

  
 -7- 

 2.4    Release and Full Settlement. Anything
in this Plan to the contrary notwithstanding, as a pre-condition to the receipt of any severance payments or benefits under Sections 2.1(a) and (b), Sections 2.2(a) and (b), Section 2.3(a) or
Section 2.3(b) above, whichever is applicable, a Covered Executive whose employment has been subject to an Involuntary Termination must execute a Release, in substantially the form attached hereto as Attachment A, releasing the Board, the
Committee, the Plan’s fiduciaries and administrators, the Employers, the Company and their respective subsidiaries, affiliates, shareholders, partners, officers, directors, executives and agents (the “Released Parties”) from any and
all claims and causes of action of any kind or character, including, but not limited to, all claims or causes of action arising out of such Covered Executive’s employment with any of the Released Parties or the termination of such employment
and deemed amendment of the outstanding Restricted Stock and Performance Share agreements as described in Section 2.3, but excluding (i) all vested benefits the Covered Executive may have under any employee benefit plan, program or
arrangement of the Employer or an affiliate that is subject to ERISA and (ii) any payments and benefits to which he is entitled to receive under this Plan as a result of the Release becoming irrevocable. The Employer’s performance of its
obligations hereunder and the receipt of the benefits provided hereunder by such Covered Executive shall constitute full settlement of all such released claims and causes of action. To be entitled to receive benefits pursuant to Sections 2.1(a) and
(b), Sections 2.2(a) and (b), Section 2.3(a) or Section 2.3(b), as applicable, such Release (i) must be executed by the Covered Executive not later than 45 days following the date the Release is provided to the Covered Executive,
which must be within five days following his Involuntary Termination, and (ii) must have become irrevocable. 

2.5    No Mitigation. A Covered Executive shall not be required to mitigate the amount of any payment
or benefit provided for in this Article II by seeking other employment or otherwise, nor shall the amount of any payment or benefit provided for in this Article II be reduced by any compensation or benefit earned by the Covered Executive as the
result of employment by another employer, except as provided in Section 2.1(b) or Section 2.2(b) with respect to his eligibility for coverage under a new employer’s group health plan. Subject to the foregoing, the benefits under the
Plan are in addition to any other benefits to which a Covered Executive is otherwise entitled. 

2.6    Severance Pay Plan Limitation. This Plan is intended to be an employee welfare benefit plan
within the meaning of section 3(1) of ERISA and the Department of Labor regulations promulgated thereunder. Therefore, anything in the Plan to the contrary notwithstanding, in no event shall any Covered Executive receive total severance payments
hereunder that exceed the equivalent of twice such Covered Executive’s “annual compensation” (as such term is defined in 29 CFR § 2510.3-2(b)(2)) during the year immediately preceding his
Involuntary Termination. If total severance payments made hereunder to a Covered Executive would otherwise exceed the limitation in the preceding sentence, the amount payable to such Covered Executive shall be reduced as necessary to satisfy such
limitation. 

  
 -8- 

 III. 

ADMINISTRATION OF PLAN 

3.1    Committee’s Powers and Duties. The Company shall be the named fiduciary and shall have full
power to administer the Plan in all of its details, subject to applicable requirements of law. The duties of the Company shall be performed by the Committee. It shall be a principal duty of the Committee to see that the Plan is carried out, in
accordance with its terms, for the exclusive benefit of persons entitled to participate in the Plan. For this purpose, the Committee’s powers shall include, but not be limited to, the following authority, in addition to all other powers
provided by this Plan: 
 (a)    to make and enforce such rules and regulations as it deems necessary or proper for the
efficient administration of the Plan; 
 (b)    to interpret the Plan and all facts with respect to a claim for payment
or benefits, its interpretation thereof to be final and conclusive on all persons claiming payment or benefits under the Plan; 

(c)    to decide all questions concerning the Plan and the eligibility of any person to participate in the Plan; 

(d)    to make a determination as to the right of any person to a payment or benefit under the Plan (including, without
limitation, to determine whether and when there has been a termination of a Covered Executive’s employment and the cause of such termination and the amount of such payment or benefit); 

(e)    to appoint such agents, counsel, accountants, consultants, claims administrator and other persons as may be
required to assist in administering the Plan; 
 (f)    to allocate and delegate its responsibilities under the Plan and
to designate other persons to carry out any of its responsibilities under the Plan, any such allocation, delegation or designation to be in writing; 

(g)    to sue or cause suit to be brought in the name of the Plan; and 

(h)    to obtain from the Employer and from Covered Executives such information as is necessary for the proper
administration of the Plan. 
 3.2    Member’s Own Participation. No member of the Committee may act
or vote in a decision of the Committee specifically relating to himself as a participant in the Plan. 

3.3    Indemnification. The Employer shall indemnify and hold harmless each member of the Committee against
any and all expenses and liabilities arising out of his administrative functions or fiduciary responsibilities, including any expenses and liabilities that are caused by or result from an act or omission constituting the negligence of such member in
the performance of such functions or responsibilities, but excluding expenses and liabilities that are caused by or result from such member’s own gross negligence or willful misconduct. Expenses against which 

  
 -9- 

 
such member shall be indemnified hereunder shall include, without limitation, the amounts of any settlement or judgment, costs, counsel fees, and related charges reasonably incurred in connection
with a claim asserted or a proceeding brought or settlement thereof. 
 3.4    Compensation, Bond and
Expenses. The members of the Committee shall not receive compensation with respect to their services for the Committee. To the extent required by applicable law, but not otherwise, Committee members shall furnish bond or security for the
performance of their duties hereunder. Any expenses properly incurred by the Committee incident to the administration, termination or protection of the Plan, including the cost of furnishing bond, shall be paid by the Company. 

3.5    Claims Procedure. Any Covered Executive that the Committee determines is entitled to a benefit under
the Plan is not required to file a claim for benefits. Any Covered Executive who is not paid a benefit and who believes that he is entitled to a benefit or who has been paid a benefit and who believes that he is entitled to a greater benefit may
file a claim for benefits under the Plan in writing with the Committee. In any case in which a claim for Plan benefits by a Covered Executive is denied or modified, the Committee shall furnish written notice to the claimant within 90 days after
receipt of such claim for Plan benefits (or within 180 days if additional information requested by the Committee necessitates an extension of the 90-day period and the claimant is informed of such extension in
writing within the original 90-day period), which notice shall: 
 (a)    state
the specific reason or reasons for the denial or modification; 
 (b)    provide specific reference to pertinent Plan
provisions on which the denial or modification is based; 
 (c)    provide a description of any additional material or
information necessary for the Covered Executive or his representative to perfect the claim, and an explanation of why such material or information is necessary; and 

(d)    explain the Plan’s claim review procedure as contained herein. 

In the event a claim for Plan benefits is denied or modified, if the Covered Executive or his representative desires to have such denial or modification
reviewed, he must, within 60 days following receipt of the notice of such denial or modification, submit a written request for review by the Committee of its initial decision. In connection with such request, the Covered Executive or his
representative may review any pertinent documents upon which such denial or modification was based and may submit issues and comments in writing. Within 60 days following such request for review the Committee shall, after providing a full and fair
review, render its final decision in writing to the Covered Executive and his representative, if any, stating specific reasons for such decision and making specific references to pertinent Plan provisions upon which the decision is based. If special
circumstances require an extension of such 60-day period, the Committee’s decision shall be rendered as soon as possible, but not later than 120 days after receipt of the request for review. If an
extension of time for review is required, written notice of the extension shall be furnished to the Covered Executive and his representative, if any, prior to the commencement of the extension period. Any legal action with respect to a claim for

  
 -10- 

 
Plan benefits must be filed no later than one year after the later of (1) the date the claim is denied by the Committee or (2) if a review of such denial is requested pursuant to the
provisions above, the date of the final decision by the Committee with respect to such request. 
 IV. 

GENERAL PROVISIONS 

4.1    Funding. The benefits provided herein shall be unfunded and shall be provided from the
Employer’s general assets. 
 4.2    Cost of Plan. Except as provided in Section 2.1(b) and
Section 2.2(b) with respect to the active employee monthly premium charged for Health Benefit Coverages, the entire cost of the Plan shall be borne by the Employer and no contributions shall be required of the Covered Executives. 

4.3    Plan Year. The Plan shall operate on a calendar year basis. 

4.4    Participating Employers. GPC LLC shall be an Employer. The Committee may designate any other
affiliate of GPC LLC eligible by law to participate in this Plan as also being an Employer by written instrument delivered to the Secretary of the Company and the other designated Employer. Such written instrument shall specify the effective date of
such designated participation, may incorporate specific provisions relating to the operation of the Plan which apply to the designated Employer only and shall become, as to such designated Employer and its executives, a part of the Plan. Each
designated Employer shall be conclusively presumed to have consented to its designation and to have agreed to be bound by the terms of the Plan and any and all amendments thereto upon its submission of information to the Committee required by the
terms of or with respect to the Plan; provided, however, that the terms of the Plan may be modified so as to increase the obligations of an Employer only with the written consent of such Employer. Notwithstanding anything herein to the contrary, if
a Covered Executive’s employment is transferred to an affiliate of the Employer that has not been designated an “Employer” under the Plan, for purposes of this Plan, during the six-month period
following such transfer such affiliate shall be deemed to be an Employer for all purposes with respect to such transferred Covered Executive. 

4.5    Amendment and Termination. The term of the Plan, as amended and restated hereby, shall continue
through the third anniversary of the Effective Date, and automatically shall then terminate unless the Board takes action prior to such third anniversary of the Effective Date to provide that the term of the Plan shall be extended. Subject to the
following paragraph, the Board may amend or terminate the Plan at any time; provided, however, that no such amendment or termination may adversely affect the rights of a Covered Executive who has incurred an Involuntary Termination prior to such
amendment or termination of the Plan. 
 Notwithstanding the foregoing, if a Change of Control occurs during the term of the Plan, the Plan
may not be terminated or amended on or within 18 months following the Change of Control to adversely affect the participation and rights (contingent or otherwise) under the Plan of any individual who is a Covered Executive immediately prior to such
Change of Control. For 

  
 -11- 

 
purposes of this Section 4.5, on and following a Change of Control a revocation of the designation of an affiliate, GPC LLC or the Company as an Employer, or a transfer of a Covered
Executive’s employment to an entity that is not designated an Employer, shall be deemed to be an adverse amendment to the Plan with respect to each affected Covered Executive. The Employer’s obligation to make all payments and provide all
benefits that become (or have become) payable as a result of an Involuntary Termination that occurs during such 18-month period following the Change of Control (or which occurred prior to the Change of
Control) shall survive any termination of the Plan. 
 4.6    Not Contract of Employment. The adoption and
maintenance of the Plan shall not be deemed to be a contract of employment between the Employer and any person or to be consideration for the employment of any person. Nothing herein contained shall be deemed to give any person the right to be
retained in the employ of the Employer or to restrict the right of the Employer to discharge any person at any time nor shall the Plan be deemed to give the Employer the right to require any person to remain in the employ of the Employer or to
restrict any person’s right to terminate his employment at any time. 
 4.7    Severability. Any
provision in the Plan that is prohibited or unenforceable in any jurisdiction by reason of applicable law shall, as to such jurisdiction, be ineffective only to the extent of such prohibition or unenforceability without invalidating or affecting the
remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 

4.8    Nonalienation. Covered Executives shall not have any right to pledge, hypothecate, anticipate or
assign benefits or rights under the Plan, except by will or the laws of descent and distribution. 
 4.9    Effect
of Plan. Except with respect to any individual written employment or severance agreements between a Covered Executive and an Employer, the Company or an affiliate, this Plan supersedes all prior oral or written policies, plans or
arrangements of the Employer or the Company covering or applying to, and all prior oral or written communications to, Covered Executives with respect to the subject matter hereof, and all such prior policies, plans or arrangements and communications
are hereby null and void and of no further force and effect other than any outstanding agreements evidencing Restricted Stock or Performance Shares (which are hereby deemed amended as described herein). Further, this Plan shall be binding upon the
Employer and any successor of the Employer, by merger or otherwise, and shall inure to the benefit of and be enforceable by the Covered Executives. 

4.10    Taxes. The Employer or its successor may withhold from any amounts payable to a Covered Executive
under the Plan all taxes it is required to withhold pursuant to any applicable law or regulation. 

4.11    Governing Law. The Plan shall be interpreted and construed in accordance with the laws of the State
of Texas without regard to conflict of laws principles, except to the extent preempted by federal law. 

  
 -12- 

 4.12    Section 409A Compliance. 

(a)    Notwithstanding anything in Sections 2.1 or 2.2 to the contrary concerning the time of payment of any severance
benefit, if the Covered Executive is a “specified employee,” as defined in Treas. Reg. § 1.409A-1(i), as of his Involuntary Termination, then to the extent any amount payable under the Plan to
such Covered Executive upon or as a result of his “separation from service” under Section 2.1 or Section 2.2 would be subject to the additional tax provided by Section 409A of the Code, such amount shall not be paid to the
Covered Executive until the date that is six months after the date of his Involuntary Termination (or, if earlier than the end of the six-month period, his date of death). Such payment shall be made in a lump
sum on such delayed payment date and shall bear interest at the rate of 6% per annum from the date payment was otherwise to be made under Section 2.1 or Section 2.2 and the date the delayed amount is actually paid. 

(b)    To the extent permitted under Section 409A and the applicable Treasury Regulations thereunder, each payment to
a Covered Executive under the Plan shall be treated as a “separate payment.” 
 (c)    The Plan shall be
construed to comply with Section 409A of the Code, to the extent applicable, and, in this regard, a “termination of employment” shall mean, and must be, a “separation from service” for purposes of Section 409A of the
Code. 
 [Remainder of Page Intentionally Blank; 

Signature Page Follows] 

  
 -13- 

 IN WITNESS WHEREOF, the Company and GPC LLC each have executed this Agreement on
August 22, 2018, effective as of the Effective Date. 
  

			
	GOODRICH PETROLEUM CORPORATION
		
	By:	 	 /s/ Walter G. Goodrich

		 	Walter G. Goodrich
		 	Chairman of the Board and Chief Executive Officer
	
	GOODRICH PETROLEUM COMPANY, L.L.C.
		
	By:	 	 /s/ Walter G. Goodrich

		 	Walter G. Goodrich
		 	Chairman of the Board and Chief Executive Officer

  
 SIGNATURE
PAGE TO 
 GOODRICH PETROLEUM 

AMENDED AND RESTATED 

OFFICER SEVERANCE PLAN 

 EXHIBIT A 

NON-COMPETITION AND NON-SOLICITATION COVENANTS 

1. Non-Competition and Non-Solicitation. As a condition of the
Executive Officer’s employment by the Employer, and in order to protect the Employer’s trade secret and other confidential information and the Employer’s other legitimate business interests, including the Employer’s goodwill and
customer and client relationships and for good and valuable consideration, including the benefits set forth in the Goodrich Petroleum Amended and Restated Officer Severance Plan to which this Exhibit A is attached, the Executive Officer covenants
and agrees that, without prior written consent from the Employer, during the Prohibited Period, the Executive Officer shall not, directly or indirectly, for the Executive Officer or on behalf of or in conjunction with any person or entity of any
nature: 
 (a)    engage or participate in competition with the Employer within the Market Area in any aspect of the
Business, which prohibition shall prevent the Executive Officer from directly or indirectly owning, managing, operating, joining, becoming an officer, director, employee or consultant of, or loaning money to, or selling or leasing equipment or real
estate to, or otherwise being affiliated with any person or entity engaged in, or planning to engage in, the Business in the Market Area in competition, or anticipated competition, with the Employer; 

(b)    appropriate any Business Opportunity of the Employer located in the Market Area; 

(c)    solicit, canvass, approach, encourage, entice or induce any customer or supplier of the Employer to cease or lessen
such customer’s or supplier’s business with the Employer; or 
 (d)    solicit, canvass, approach, encourage,
entice or induce any employee or contractor of the Employer to terminate his, her or its employment or engagement with the Employer. 
 Nothing herein shall
prohibit the Executive Officer from being a passive owner of not more than 1% of the outstanding stock of any class of securities of any person listed on a national securities exchange which is engaged in the Business, so long as the Executive
Officer has no active participation in the Business of such person and does not serve on the board of directors or similar body of such person. 
 2.
Definitions. For purposes of these Non-Competition and Non-Solicitation Covenants, the following terms shall have the following meanings: 

(a)    “Business” shall mean the business and operations that are the same or similar to those performed by the
Employer for which the Executive Officer provides services or about which the Executive Officer obtains trade secrets or other confidential information of the Employer during the period that the Executive Officer is employed by the Employer, which
business and operations include the exploration, development and production of natural gas and crude oil. 

  
 EXHIBIT A

 (b)    “Business Opportunity” shall mean any commercial,
investment or other business opportunity in the Business. 
 (c)    “Market Area” shall mean (i) the
Haynesville Shale, the Haynesville/Bossier Shale Angelina River Trend, and the Tuscaloosa Marine Shale; (ii) the following parishes in Louisiana: Allen, Avoyelles, Beauregard, Catahoula, Concordia, East Feliciana, East Baton Rouge, Evangeline,
Grant, Livingston, Pointe Coupee, Rapides, St. Helena, St. Landry, St. Tammany, Tangipahoa, Vernon, Washington, and West Feliciana; (iii) a one (1) mile area surrounding the outermost boundary of each lease or property owned by the
Employer immediately prior to the point in time the Executive Officer is no longer employed by the Employer and (iv) the lands covered by any lease or property under substantial consideration or evaluation by the Employer but not yet acquired
prior to the Executive Officer’s Separation from Service for which the Executive Officer provided services or about which the Executive Officer received any confidential information. 

(d)    “Prohibited Period” shall mean the period during which the Executive Officer is employed by the Employer
and continuing for a period of twelve (12) months following the date that the Executive Officer is no longer employed by the Employer, regardless of the reason for such separation. 

3. Executive Officer Representations. The Executive Officer agrees and acknowledges that the limitations and restrictions set forth herein, including
geographical and temporal restrictions on certain activities, are reasonable in all respects, will not cause the Executive Officer undue hardship, and are intended and necessary to prevent unfair competition and to protect the Employer’s
legitimate business interests. 
 4. Modification. In the event any court or arbitrator of competent jurisdiction shall determine that the scope,
time or territorial restrictions set forth in this Exhibit A are unreasonable, then such restrictions shall be enforced to the fullest extent which such court or arbitrator deems reasonable, and the terms of this Exhibit A shall thereby be reformed.

  

	
	ACCEPTED AND AGREED:
	
	EXECUTIVE OFFICER
	
	  

  
 EXHIBIT A

 -2-TEXTED
MARKED BY [***] HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND WAS FILED SEPARATELY WITH THE SECURITIES
AND EXCHANGE COMMISSION

 

Exhibit
10.1

 

EXECUTION
VERSION

 

CLINICAL
TRIAL RESEARCH AGREEMENT

 

This
CLINICAL TRIAL RESEARCH AGREEMENT (this “AGREEMENT”) is entered into on August 20, 2018 (the “Effective Date”),
by and between H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., with a primary location at 12902 Magnolia Drive,
Tampa, FL 33612-9497, hereinafter called “INSTITUTION,” and Lixte Biotechnology Holdings, Inc., with its office and
place of business at 248 Route 25A, No. 2, East Setauket, NY, hereinafter called “LIXTE.” (“INSTITUTION”
and “LIXTE”, each referred to as a “Party” and together, “Parties”)

 

WHEREAS,
INSTITUTION is dedicated to undertaking research for the purpose of discovering and making available to the public new and improved
disease treatments;

 

WHEREAS,
INSTITUTION desires to conduct a clinical research protocol which it has conceived and designed, with input from Lixte;

 

WHEREAS,
the STUDY (defined below) contemplated by this Agreement is of mutual interest and benefit to INSTITUTION and LIXTE, and will
further INSTITUTION’s instructional, basic science, clinical science and fundamental research objectives in a manner consistent
with its status as a nonprofit educational and health care institution; and

 

WHEREAS,
LIXTE, consistent with its commitment to clinical research, wishes to provide certain support to INSTITUTION on the terms and
conditions described in this AGREEMENT.

 

PRINCIPAL
INVESTIGATOR (named in Article 2 below) and INSTITUTION desire to study the safety and/or efficacy of LB-100 For Injection (the
“STUDY DRUG”) for certain clinical trial research to be conducted during the term of and pursuant to the terms and
conditions set forth in this Agreement, as further described herein (the “STUDY”). The Parties agree as follows:

 

1.
Scope of Work

 

The
STUDY to be performed under this AGREEMENT shall be performed in accordance with the terms of the final protocol, as developed
by PRINCIPAL INVESTIGATOR, with input from Lixte, including as it may be amended in accordance with the terms of this AGREEMENT,
entitled “A Ph1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1
Risk Myelodysplastic Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy,” (the “PROTOCOL”)
set forth in Exhibit A and incorporated into this AGREEMENT by reference. INSTITUTION certifies that, to its best knowledge, its
facilities, resources and population are adequate to perform the STUDY contemplated by this AGREEMENT and the PROTOCOL.
INSTITUTION and PRINCIPAL INVESTIGATOR (named in Article 2 below) agree that all aspects of the STUDY will be conducted in conformity
with all applicable federal, state, local laws, regulations including CFR Title 21, Part 312, and the principles of good clinical
practice as laid down by the ICH topic E6, Note for Guidance on Good Clinical Practice CPMP/ICH/135/95 (hereinafter referred to
as “GCP”). INSTITUTION further agrees not to conduct any research activities with the STUDY DRUG which are contrary
to the provisions of the PROTOCOL or outside the scope of the PROTOCOL. INSTITUTION shall be the legal sponsor of the PROTOCOL
and the STUDY. PRINCIPAL INVESTIGATOR and INSTITUTION will undertake the STUDY and will fulfill the requisite sponsor duties and
obligations in conducting the STUDY as defined in the Federal Regulations and Guidance Documents.

 

    	 

    	 

    

 

It
is anticipated that (i) the STUDY shall commence promptly following the Effective Date, but in no event more than six (6) months
from the Effective Date, and (ii) INSTITUTION and PRINCIPAL INVESTIGATOR shall use reasonable efforts to complete the STUDY within
twenty-four (24) months of the Effective Date, but in no event more than thirty six (36) months after the Effective Date. The
STUDY shall be deemed to have commenced when INSTITUTION enters the first patient on the clinical trial contemplated under the
STUDY (the “STUDY COMMENCEMENT”; “COMMENCE THE STUDY” has the correlative meaning).

 

2.
PRINCIPAL INVESTIGATOR

 

INSTITUTION’S
principal investigator is Rami Komrokji, MD, (“PRINCIPAL INVESTIGATOR”). PRINCIPAL INVESTIGATOR will be responsible
for the direction and supervision of all STUDY efforts in accordance with this AGREEMENT, including the organization and overall
responsibility of any subsites, in accordance with applicable INSTITUTION policies, the PROTOCOL and this AGREEMENT and Federal
Regulations. In the event that the PRINCIPAL INVESTIGATOR who signs either the Protocol and/or this AGREEMENT leaves or is removed
from the INSTITUTION, then INSTITUTION shall, within thirty (30) days of such departure by PRINCIPAL INVESTIGATOR, provide written
notice of such event to LIXTE. Any successor to PRINCIPAL INVESTIGATOR must be approved, in writing, by LIXTE and such successor
shall be required to agree to all the terms and conditions of the PROTOCOL and this AGREEMENT and to sign each such document as
evidence of such agreement (although failure to so sign will not relieve such successor from abiding with all the terms and conditions
of the Protocol and this AGREEMENT).

 

INSTITUTION
represents and certifies that it will not knowingly use in any capacity, in connection with any services to be performed under
this AGREEMENT, any individual who has been debarred pursuant to the Federal Food, Drug and Cosmetic Act, or excluded from a federal
healthcare program.

 

INSTITUTION
and/or PRINCIPAL INVESTIGATOR agrees to immediately inform LIXTE in writing if any person who is performing services hereunder
is debarred or if any action, suit, claim, investigation or legal or administrative proceeding is pending, or, to the best of
INSTITUTION’S knowledge, is threatened, relating to the debarment of INSTITUTION or any person performing services hereunder.
INSTITUTION acknowledges that no action, suit, claim, investigation or legal or administrative proceeding is pending or threatened
relating to PRINCIPAL INVESTIGATOR’S debarment and PRINCIPAL INVESTIGATOR will inform LIXTE in writing promptly, but in
no event within more than two (2) days, if any such action, suit, claim, investigation or legal or administrative proceeding is
threatened or commenced for PRINCIPAL INVESTIGATOR’S debarment.

 

    	2

    	 

    

 

3.
Inspection Rights

 

It
is agreed that LIXTE or others designated by LIXTE may, at mutually agreeable times and with prior written notice, during normal
business hours prior to the STUDY COMMENCEMENT, during the STUDY and for a reasonable time after completion or early termination
of the STUDY (not to exceed three (3) years), arrange with PRINCIPAL INVESTIGATOR or his/her designee:

 

	 	(i)
    	to
    examine and inspect qualifications of the staff and INSTITUTION facilities required for performance of the STUDY according
    to GCP requirements (to the extent the GCP requirements are adopted by the United States Food and Drug Administration (“FDA”));
	 	 	 
	 	(ii)	to
    inspect and make copies of all data and supporting study documentation as defined in E6(R2) Good Clinical Practice: Integrated
    Addendum to ICH E6(R1)(FDA Guidance for Industry March 2018) necessary for LIXTE to confirm that the STUDY is being conducted
    in conformance with the PROTOCOL and this AGREEMENT, and in compliance with all applicable legal and regulatory requirements,
    including without limitation, any applicable requirements of the FDA; and if at any time (whether or not in connection with
    an inspection) LIXTE identifies any deficiencies with respect to the foregoing, the INSTITUTION will address these deficiencies
    with appropriate corrective action and development and implementation of a prevention plan.
	 	 	 
	 	(iii)	LIXTE
    agrees to not use any monitor or auditor to inspect or audit INSTITUTION if such person is, to the best of its knowledge,
    a former employee of INSTITUTION. All monitoring and audits will be conducted in accordance with INSTITUTION’s policies
    and procedures regarding access to its facilities and information systems. LIXTE will not, for the period of this AGREEMENT
    and for two (2) years thereafter, directly or indirectly solicit for employment any person who participated in the STUDY and
    at the time of such solicitation is employed or retained by INSTITUTION without the prior written consent of INSTITUTION.

 

    	3

    	 

    

 

4.
Clinical Trial Approvals

 

A.
LIXTE shall be responsible for the following:

 

		(i)	IND
                                         Lixte will hold the IND and file the protocol with sample informed consent to the FDA
                                         including the signed FDA Form1572.

 

B.
INSTITUTION shall be responsible for obtaining the following:

 

	 	(i)	approval of the Protocol, any informed consent relating
to the STUDY and advertisement, if any, pertaining to the enrollment of subjects in the STUDY by the appropriate Institutional
Review Board (“IRB”) prior to beginning the STUDY on human subjects;
	 	 	 
	 	(ii)	an informed consent which complies with all applicable
federal, state, and local laws and regulations signed by each human subject prior to the subject’s participating in the
STUDY; and PRINCIPAL INVESTIGATOR will not represent in the informed consent or elsewhere that LIXTE is the STUDY sponsor; and
	 	 	 
	 	(iii)	informed consent shall provide subject consent to allow
PRINCIPAL INVESTIGATOR to disclose personal health information to LIXTE and its representatives who will use such information
to evaluate the STUDY DRUG. Subject’s information may also be shared with the FDA and with health authorities in other countries.
	 	 	 
	 	(iii)	All other essential documents and recordkeeping requirements
as defined under GCPs.

 

B.
In the event the IRB requires changes in the Protocol or informed consent, LIXTE shall be advised in advance of and shall have
the right to approve all modifications to the Protocol and informed consent. INSTITUTION and PRINCIPAL INVESTIGATOR shall not
modify the STUDY described in the PROTOCOL once finalized and after approval by the IRB without the prior written approval of
LIXTE; provided, however, that PRINCIPAL INVESTIGATOR shall be permitted to deviate from the Protocol if necessary to address
concerns for the safety, health or welfare of the Study subjects, provided that PRINCIPAL INVESTIGATOR shall provide prompt notice
of same to LIXTE.

 

C.
The PRINCIPAL INVESTIGATOR and INSTITUTION shall ensure that IRB approval shall be maintained current at all times and in the
event that the STUDY continues beyond the period of the initial IRB approval, shall ensure that appropriate periodic IRB re-approval
is obtained without lapse in approval status.

 

D.
In the event that IRB approval lapses, becomes suspended, or is withdrawn, PRINCIPAL INVESTIGATOR or INSTITUTION shall notify
LIXTE within 24 hours of that event and IRB’s reasons for approval lapse, suspension or withdrawal.

 

    	4

    	 

    

 

5.
Term of Agreement

 

The
term of this AGREEMENT shall be five (5) years from the execution of this AGREEMENT, unless early terminated pursuant to Section
6 below. The obligations set forth in Sections 9, 10 and 12, to the extent applicable, shall extend for a period of five (5) years
after termination of this AGREEMENT.

 

6.
Termination

 

A.
LIXTE may terminate this AGREEMENT by giving thirty (30) days written notice to
the other party. In the event thirty (30) days is determined by either party to be insufficient notice based upon evaluation of
risks to enrolled research subject(s) then receiving the STUDY DRUG, the parties will cooperate to safely withdraw subjects from
drug treatment over a mutually agreeable period of time but in no event shall LIXTE’s obligation to supply STUDY DRUG hereunder
extend beyond a reasonable period. Notwithstanding the foregoing, in the event LIXTE or INSTITUTION (1) believes that immediate
termination is necessary due to an evaluation of risks to enrolled research subject(s), or (2) is informed that approval to conduct
the Study has been withdrawn by the FDA, IRB or other applicable regulatory authority, LIXTE or INSTITUTION, as applicable, may
terminate this AGREEMENT immediately.

 

B.
Notwithstanding any other provision hereof, either party shall be entitled to terminate this AGREEMENT for any Material Breach.
A Material Breach by INSTITUTION shall be defined as:

 

	 	(i)	INSTITUTION
    fails to COMMENCE THE STUDY within six (6) months after the Effective Date or fails to complete the STUDY within thirty six
    (36) months after the Effective Date.
	 	 	 
	 	(ii)
    	INSTITUTION’S
    failure to comply with its obligations, responsibilities and the terms and conditions of this AGREEMENT and the Protocol;
	 	 	 
	 	(iii)	INSTITUTION’S
    failure to comply with: (a) its obligations for keeping LIXTE informed of all necessary and relevant information in connection
    with the Protocol; (b) any applicable law, rule or regulation relevant to the STUDY; or (c) the Protocol regarding the work
    to be performed under this AGREEMENT.

 

C.
In the event of any termination:

 

	 	(i)	INSTITUTION
    shall return to LIXTE, at LIXTE’s expense, all unused materials, including but not limited to, STUDY DRUG and clinical
    supplies (unless written authorization to retain or destroy them is given by LIXTE in which case INSTITUTION shall comply
    with the applicable provisions of Article 11 hereof);

 

    	5

    	 

    

 

	 	(ii)	the
    parties agree that (a) LIXTE will make all payments due hereunder to INSTITUTION for work actually performed in accordance
    with the Protocol as of the date of notice of termination, and (b) LIXTE will pay for any non-cancelable costs (as defined
    in Exhibit B) incurred, except where the termination is for INSTITUTION’s material breach, in which case INSTITUTION
    shall waive any payment for non-cancelable costs and shall pay for all costs associated with the breach, and;
	 	 	 
	 	(iii)	PRINCIPAL
    INVESTIGATOR shall return to LIXTE, at LIXTE’s expense, all CONFIDENTIAL INFORMATION (as defined in Article 9 hereof)
    owned or controlled by LIXTE and in the possession of INSTITUTION.

 

D.
The termination of this AGREEMENT shall not relieve either party of its obligation to the other in respect of:

 

	 	(i)	retaining
    in confidence all CONFIDENTIAL INFORMATION (as defined in Article 9 hereof) ;
	 	 	 
	 	(ii)	complying
    with record keeping and reporting obligations (under Article 7 hereof);
	 	 	 
	 	(iii)
    	complying
    with any publication obligations (under Article 10 hereof) and obtaining any written approval and consents for any publicity
    and promotional purposes (under Article 18 hereof);
	 	 	 
	 	(iv)	complying
    with obligations relating to clinical supplies (under Article 11 hereof);
	 	 	 
	 	(v)	indemnification
    and insurance obligations (under Article 12 hereof); and
	 	 	 
	 	(vi)
    	inspection
    rights (under Article 3 hereof);

 

all
of which obligations are binding on the appropriate party and shall remain in full force and effect as set forth in this AGREEMENT.

 

E.
INSTITUTION shall not disclose to LIXTE or induce LIXTE to use any secret or confidential information or material belonging to
others, or without prior notice to LIXTE, use in the STUDY any proprietary compounds or materials of any third party, including
other sponsors of other clinical trials.

 

7.
Records and Reports

 

A.
PRINCIPAL INVESTIGATOR and INSTITUTION shall have the following record keeping and reporting obligations:

 

	 	(i)	preparation
    and maintenance of complete, accurately written records, accounts, notes, reports, STUDY files and data (Case Report Forms/Electronic
    Data Capture) relating to the STUDY under this AGREEMENT; and

 

    	6

    	 

    

 

	 	(ii)	conduct
    of the STUDY and maintenance of records and data during and after the term or early termination of this AGREEMENT in compliance
    with all applicable legal and regulatory requirements, including without limitation, any applicable requirements of the FDA.
	 	 	 
	 	(iii)	Preparation
    and submission of periodic progress reports as requested by LIXTE which will include the following (but is not limited to):
	 	 	(a)
    Enrollment summaries,
	 	 	(b)
    Enrollment forecasting for drug supply management,
	 	 	(c)
    Final study report or acceptable equivalent according to specified content within a reasonable time after completion of the
    STUDY but in no event longer than three (3) months after completion of the STUDY.
	 	 	(d)
    Electronic copy of the final data set used in support of the final study report in SAS or other usable data format (non-PDF)
    suitable for inclusion in future regulatory submissions.
	 	 	 
	 	(iv)	PRINCIPAL
    INVESTIGATOR and/or INSTITUTION shall be the responsible party as defined in Section §801 of the Food and Drug Administration
    Amendments Act of 2007. PRINCIPAL INVESTIGATOR and/or INSTITUTION, as the responsible party, shall submit the required clinical
    trial information to the Director of the National Institutes of Health (NIH) for inclusion in the registry and results database
    via Clinicaltrials.gov within twenty-one (21) days after the first patient is enrolled in this clinical investigation.

 

B.
INSTITUTION and PRINCIPAL INVESTIGATOR further agree to report adverse events, including Expedited Alert Reports to LIXTE and
to relevant regulatory agencies, in compliance with all applicable legal and regulatory requirements and in fulfillment of the
requisite duties and obligations in conducting the STUDY.

 

C.
PRINCIPAL INVESTIGATOR shall notify INSTITUTION, and LIXTE within one (1) working day after learning of any defect or possible
defect associated with the STUDY DRUG provided by LIXTE.

 

8.
Funding

 

The
IND will be filed in the name of, and be owned by, LIXTE. LIXTE will provide funding for up to forty-seven (47) patients at the
rate specified in the Budget which is attached as Exhibit B and which is incorporated into this AGREEMENT by reference. The Parties
acknowledge that the actual costs of the STUDY may exceed the amounts specified in the Budget and that LIXTE shall have no obligation
to pay any amount in excess of those specified in the Exhibit B as payable by LIXTE.

 

    	7

    	 

    

 

9.
CONFIDENTIAL INFORMATION

 

A.
During and for a period of five (5) years after the term or early termination of this AGREEMENT, INSTITUTION and PRINCIPAL INVESTIGATOR
shall retain in confidence all test articles and proprietary data and/or information obtained from LIXTE, including, but not limited
to, the investigator’s brochure and any other information or material disclosed under secrecy agreements previously entered
into between the parties (“CONFIDENTIAL INFORMATION”). This restriction shall not apply to CONFIDENTIAL INFORMATION:

 

	 	(i)	which
    is or becomes public knowledge (through no fault of INSTITUTION or PRINCIPAL INVESTIGATOR); or
	 	 	 
	 	(ii)	which
    is lawfully made available to INSTITUTION or PRINCIPAL INVESTIGATOR by an independent third party owing no obligation of confidentiality
    to LIXTE with regard thereto (and such lawful right can be properly demonstrated by INSTITUTION or PRINCIPAL INVESTIGATOR);
    or
	 	 	 
	 	(iii)	which
    is already in INSTITUTION’S or PRINCIPAL INVESTIGATOR’S possession at the time of receipt from LIXTE (and such
    prior possession can be properly demonstrated by INSTITUTION or PRINCIPAL INVESTIGATOR); or
	 	 	 
	 	(v)	which
    is independently developed by INSTITUTION or PRINCIPAL INVESTIGATOR (and such independent development can be properly demonstrated
    by INSTITUTION or PRINCIPAL INVESTIGATOR);
	 	 	 
	 	(vi)	which
    is approved for release through prior written authorization of LIXTE;
	 	 	 
	 	(vii)	which
    is published in accordance with the express terms of Section 10(B) this AGREEMENT; or
	 	 	 
	 	(v)
    	which
    is required by law, regulation, rule, act or order of any governmental authority or agency to be disclosed by INSTITUTION.

 

B.
To permit LIXTE an opportunity to intervene by seeking a protective order or other similar order, in order to limit or prevent
disclosures of CONFIDENTIAL INFORMATION, INSTITUTION or PRINCIPAL INVESTIGATOR shall promptly notify LIXTE, in writing, if it
is requested by a court order, a governmental agency, or any other entity to disclose CONFIDENTIAL INFORMATION in INSTITUTION’S
or PRINCIPAL INVESTIGATOR’S possession and thereafter INSTITUTION or PRINCIPAL INVESTIGATOR shall disclose only the minimum
CONFIDENTIAL INFORMATION required to be disclosed in order to comply, whether or not a protective order or other similar order
is obtained by LIXTE.

 

    	8

    	 

    

 

C.
Subject to applicable federal, state or local legal and regulatory requirements, INSTITUTION and PRINCIPAL INVESTIGATOR agree
to promptly return to LIXTE, upon its request and at its expense, and only if legally permissible, all CONFIDENTIAL INFORMATION
obtained from LIXTE or belonging to LIXTE pursuant to this AGREEMENT; provided, however, that INSTITUTION may retain one copy
of CONFIDENTIAL INFORMATION in a secure location for purposes of identifying INSTITUTION’S obligations under these confidentiality
provisions.

 

D.
INSTITUTION and PRINCIPAL INVESTIGATOR shall limit disclosure of CONFIDENTIAL INFORMATION received hereunder to only those of
its representatives, agents, officers and employees (collectively, “AGENTS”) who are directly involved with the STUDY
and only on a need to know basis. INSTITUTION shall advise its AGENTS upon disclosure to them of any CONFIDENTIAL INFORMATION
of the proprietary nature thereof and the terms and conditions of this AGREEMENT and shall use all reasonable safeguards to prevent
unauthorized disclosure by such AGENTS. INSTITUTION shall be responsible for any breach of these confidentiality provisions by
its AGENTS.

 

E.
INSTITUTION acknowledges and expressly agrees that any disclosure of CONFIDENTIAL INFORMATION in violation of this AGREEMENT may
be detrimental to LIXTE’s business and cause it irreparable harm and damage. In accordance with applicable law and in addition
to any other rights and remedies provided herein, LIXTE shall be entitled to seek equitable relief by way of injunction or otherwise.

 

F.
Information regarding INSTITUTION’s business practices (i.e., health care delivery practices, utilization data, membership
or other health plan information) (“INSTITUTION CONFIDENTIAL INFORMATION”), the PROTOCOL, data and patient medical
records unrelated to the STUDY (originating at the INSTITUTION) from which the data for the STUDY is collected shall be deemed
INSTITUTION Confidential Information and shall continue to be the sole and exclusive property of INSTITUTION. LIXTE agrees to
treat INSTITUTION Confidential Information in the same confidential manner and subject to the same use and disclosure limitations
to which INSTITUTION and PRINCIPAL INVESTIGATOR are subject with respect to LIXTE’s Confidential Information.

 

10.
Data, Publications and Other Rights

 

a.
Without limiting LIXTE’s rights in LIXTE CONFIDENTIAL INFORMATION provided by LIXTE to INSTITUTION hereunder (which
shall at all times remain the exclusive property of LIXTE), LIXTE agrees that all new research data and results generated
solely by INSTITUTION during the course of the STUDY (the “RESULTS”) shall be the sole and exclusive property of
INSTITUTION; provided, however, that LIXTE (i) shall be provided access to all RESULTS, and is hereby granted a
non-exclusive, irrevocable, perpetual, transferable and sublicensable license to use the RESULTS for any lawful purpose, and
(ii) shall have the right to access and use SAMPLES (as defined in Article 15 herein) for any purpose permitted by the
informed consent and/or this Agreement. For the avoidance of doubt, the term “RESULTS” does not include any
CONFIDENTIAL INFORMATION or intellectual property rights of LIXTE.

 

    	9

    	 

    

 

b.
In recognition of the importance of disseminating information relating to any novel or important observations or results
arising from the STUDY and understanding that such need must be balanced with LIXTE’s obligations to maintain control
over CONFIDENTIAL INFORMATION as well as to comply with appropriate rules and regulations of the FDA, and for LIXTE’S
to exercise its rights in intellectual property and to file patent applications, as set forth herein and in the Exclusive
License Agreement (defined below), the parties hereby agree to the following:

 

		i.	Subject
                                         to the terms and conditions of this AGREEMENT, including without limitation LIXTE’s
                                         prior right of review pursuant to Section 10(B)(ii), (a) INSTITUTION has the right and
                                         is encouraged to publicly present and/or publish RESULTS in a peer-reviewed journal and
                                         (b) if RESULTS do not merit publication in a peer-reviewed journal or if INSTITUTION
                                         does not intend to publish RESULTS in a peer-reviewed journal then INSTITUTION may make
                                         the RESULTS available by an alternative means such as ClinicalStudyResults.org, which
                                         is consistent with PhRMA Principles on the Conduct of Clinical Trials Communication and
                                         Clinical Trial Results. INSTITUTION shall acknowledge LIXTE as a supporter of the Study
                                         in any such presentation, publication or distribution.

 

		ii.	PRINCIPAL
                                         INVESTIGATOR and INSTITUTION agree not to publish, publicly present, or distribute by
                                         alternative means (as set forth in Section 10(B)(i)) any interim or final RESULTS of
                                         the STUDY, or any other information related to the STUDY or the Protocol, without the
                                         prior written review of LIXTE, as provided below. PRINCIPAL INVESTIGATOR and INSTITUTION
                                         further agree to provide thirty (30) days written notice to LIXTE prior to submission
                                         for publication, presentation or distribution to permit LIXTE to review drafts of abstracts
                                         and manuscripts for publication (including, without limitation, slides and texts of oral
                                         or other public presentations and texts of any transmission through any electronic media,
                                         e.g. any computer access system such as the Internet, World Wide Web etc., or patent
                                         application filing, collectively or individually a “PUBLIC PRESENTATION”)
                                         which report any RESULTS arising out of the STUDY. LIXTE shall have the right to review
                                         and comment, with respect to a PUBLIC PRESENTATION, including but not limited to, the
                                         data analysis and presentation and to ensure that CONFIDENTIAL INFORMATION is not disclosed
                                         in violation of this AGREEMENT and to exercise LIXTE’S rights in intellectual property
                                         and to file patent applications, as set forth herein and in the Exclusive License Agreement.

 

    	10

    	 

    

 

		iii.	If
                                         the parties disagree concerning the accuracy and appropriateness of the data analysis
                                         and presentation, and/or confidentiality of LIXTE’s CONFIDENTIAL INFORMATION, INSTITUTION
                                         agrees to meet with LIXTE’s representatives at the clinical STUDY site or as otherwise
                                         agreed, prior to submission of a PUBLIC PRESENTATION, for the purpose of making good
                                         faith efforts to discuss and resolve any such issues or disagreement.

 

D.
No PUBLIC PRESENTATION shall contain any CONFIDENTIAL INFORMATION of LIXTE and shall be confined to new discoveries and
interpretations of scientific fact.

 

E.
If LIXTE believes there is patentable subject matter contained in any PUBLIC PRESENTATION submitted for review, LIXTE shall
promptly identify such subject matter to INSTITUTION. If LIXTE requests and at LIXTE’s expense, INSTITUTION shall delay
such PUBLIC PRESENTATION for a reasonable period of time, up to ninety (90) days, until such patent application covering the
subject matter is properly filed and shall use reasonable efforts to assist LIXTE, at LIXTE’s expense, to file such
patent application.

 

11.
STUDY DRUG

 

LIXTE
shall make available sufficient quantities of LB-100 for Injection free of charge as reasonably necessary to carry out the STUDY,
it being understood that INSTITUTION and PRINCIPAL INVESTIGATOR shall take responsibility to maintain appropriate records and
assure appropriate supply, handling, storage, distribution and usage of these materials in accordance with the Protocol and any
applicable laws and regulations relating thereto and that it shall not be transferred to any other person without the knowledge
of LIXTE. STUDY DRUG shall be provided at no cost to STUDY subjects and may not be used for any other purpose than that stated
in the Protocol. All unused materials will be returned, at LIXTE’s expense, to LIXTE or its agent by INSTITUTION at the
conclusion of the STUDY or upon earlier termination of this AGREEMENT, unless written authorization to destroy or retain them
is given by LIXTE. If authorization to destroy unused material is given, INSTITUTION is responsible for drug accountability and
destruction according to ICH/GCP guidelines and all applicable local laws. In addition to the other requirements under this AGREEMENT
and the Protocol, in the event a re-supply of STUDY DRUG is required in order to continue to conduct the STUDY in accordance with
this AGREEMENT and the Protocol, it will be done conditional on LIXTE’s receipt of current IRB approval documentation.

 

Any
use of LIXTE’s STUDY DRUG, or methods of making and using the same, which are beyond the scope of the rights set forth in
this AGREEMENT shall constitute a material breach of this AGREEMENT.

 

    	11

    	 

    

 

12.
Indemnification and Insurance

 

A.
LIXTE shall indemnify, defend and hold harmless INSTITUTION, its trustees, officers, agents, faculty, directors, employees and
PRINCIPAL INVESTIGATOR, (and any named co-investigator) from and against any demands, claims, actions, proceedings or costs of
judgments which may be made or instituted against any of them by reason of personal injury (including death) to any person, or
damage to property, arising out of or connected with the failure of the STUDY DRUG to meet product specifications or from its
use or misuse of RESULTS (excluding any claim alleging that LIXTE is not permitted to use the RESULTS or claim regarding the accuracy
or completeness of the RESULTS). As a precondition for such indemnity, INSTITUTION agrees: (i) to promptly notify LIXTE of any
such claim, proceeding, investigation or suit; (ii) to cooperate fully with LIXTE, at LIXTE’s expense, in defending against
such claim, proceeding, investigation or suit, and to tender to LIXTE the right to control the defense of the foregoing; and (iii)
in the event of a proceeding or suit, to attend hearings and trials and assist in securing and giving evidence, and to use reasonable
efforts to obtain the attendance of necessary and proper witnesses, the reasonable cost of which shall be reimbursed by LIXTE.

 

B.
Notwithstanding the foregoing or anything in the Agreement to the contrary, LIXTE shall have no indemnification obligation or
liability for loss or damage resulting from:

 

	 	(i)	failure
    of INSTITUTION or PRINCIPAL INVESTIGATOR to adhere to the terms and provisions of the PROTOCOL (including agreed amendments
    thereto), this AGREEMENT, or LIXTE’s written recommendations and instructions relative to the administration and use
    of any drug substances involved in the STUDY, including, but not limited to, the STUDY DRUG, any comparative drug and any
    placebo;
	 	 	 
	 	(ii)	failure
    of INSTITUTION or PRINCIPAL INVESTIGATOR to comply with any INSTITUTION policies and procedures, applicable FDA or other governmental
    or state law, rules or regulations applicable to the performance of its obligations under this AGREEMENT;
	 	 	 
	 	(iii)	failure
    of INSTITUTION or PRINCIPAL INVESTIGATOR to conduct the STUDY in a normal, prudent manner; or
	 	 	 
	 	(iv)	negligent
    act or omission or willful misconduct by PRINCIPAL INVESTIGATOR, INSTITUTION, its trustees, officers, agents or employees
    related to the performance of services under this AGREEMENT.

 

C.
A condition of LIXTE’s indemnity obligation is that, whenever PRINCIPAL INVESTIGATOR and/or INSTITUTION has information
from which it may reasonably conclude an incident of bodily injury, death or property damage has occurred, INSTITUTION shall promptly
give notice to LIXTE of all pertinent data surrounding such incident. In addition, PRINCIPAL INVESTIGATOR and INSTITUTION shall
comply with all of their obligations with regard to adverse event reporting procedures as set forth in this AGREEMENT and the
Protocol and any appendix or attachment thereto. In the event claim is made or suit is brought, INSTITUTION and PRINCIPAL INVESTIGATOR
shall assist LIXTE, at LIXTE’s expense, and cooperate in the gathering of information with respect to the time, place, and
circumstances and in obtaining the names and addresses of the injured parties and available witnesses. PRINCIPAL INVESTIGATOR
and INSTITUTION agree to cooperate with and to authorize LIXTE to carry out sole management and defense of such claim or action.
Neither PRINCIPAL INVESTIGATOR nor INSTITUTION, its trustees, officers, agents or employees shall compromise or settle any claim
or action without the prior written approval of LIXTE, and LIXTE shall not compromise or settle any claim or action against INSTITUTION
or PRINCIPAL INVESTIGATOR without the prior written approval of INSTITUTION.

 

    	12

    	 

    

 

D.
Without limiting INSTITUTION’S and PRINCIPAL INVESTIGATOR’S obligations to comply with the terms of this Agreement,
INSTITUTION agrees to be responsible for any acts or omissions caused by gross negligence or willful misconduct by INSTITUTION
or PRINCIPAL INVESTIGATOR in connection with this Agreement to the extent permitted by applicable Florida law, and shall be financially
and legally responsible for such liabilities, costs, damages, and expenses resulting therefrom or attributable thereto. Without
limiting the foregoing or any requirements under applicable law, INSTITUTION shall have no obligation hereunder to indemnify Sponsor
and/or its agents, employees and representatives. Notwithstanding, INSTITUTION’S liability is limited in accordance with
Florida Statute 768.28.

 

E.
INSTITUTION is an instrumentality of the State of Florida pursuant to Section 1004.3, Florida Statutes, and its liability is limited
as set forth in Section 768.28, Florida Statutes. In addition, and without waiving its sovereign immunity, INSTITUTION shall maintain
commercial insurance for no less than $1,000,000 per claim and $3,000,000 in the aggregate to insure against covered losses and
damages. Upon request of LIXTE, copies of certificates evidencing such insurance coverage will be made available to LIXTE and
INSTITUTION shall provide thirty (30) days’ prior written notice to LIXTE in the event of cancellation or any material change
in such insurance.

 

F.
LIXTE is responsible, at its own expense, for insurance to cover its liability exposures.

 

G.
LIXTE shall promptly reimburse INSTITUTION for reasonable and necessary medical expenses incurred by STUDY subjects for medical
care, including hospitalization, in the diagnosis and treatment of complications, injuries or illness caused by the STUDY DRUG
following its administration in compliance with the PROTOCOL, which are not attributable to the negligence or misconduct of any
person in the employment of INSTITUTION and that would not be expected from the standard treatment using currently approved therapies.
The term “complications, injuries or illness” does not mean the natural progression of an underlying or pre-existing
condition or events that would have been expected from the standard treatment using currently approved therapies for the STUDY
subject’s condition. This section shall survive termination of this Agreement.

 

13.
Inventions and Patents

 

A.
Other than as expressly provided herein, nothing contained in this AGREEMENT shall be deemed to grant either directly or by implication,
estoppel or otherwise, any license under any patents, patent applications or other proprietary interests or discoveries of either
party.

 

    	13

    	 

    

 

B.
Title to any and all inventions, discoveries or innovations, whether patentable or not, arising directly or indirectly in connection
with the conduct of the STUDY under this AGREEMENT (“INVENTIONS”) that use or incorporate the STUDY DRUG or LIXTE’s
CONFIDENTIAL INFORMATION (“LIXTE INVENTIONS”), shall be the sole and exclusive property of LIXTE. INSTITUTION shall
notify LIXTE in writing with respect to any such LIXTE INVENTION within fifteen (15) business days of the date that the department
that handles patent matters at INSTITUTION or PRINCIPAL INVESTIGATOR becomes aware of such LIXTE INVENTION. INSTITUTION and PRINCIPAL
INVESTIGATOR hereby assign to LIXTE all rights, title and interests in and to such LIXTE INVENTIONS. LIXTE shall have the sole
and exclusive right to obtain, at its option, patent protection in the United States and foreign countries on any LIXTE INVENTION.
LIXTE hereby grants to INSTITUTION a limited, non-exclusive, non-transferable and non-sublicensable license under such LIXTE INVENTION,
solely for internal non-commercial, academic, research and patient care purposes. All INVENTIONS other than LIXTE INVENTIONS shall
be owned by INSTITUTION if invented solely by INSTITUTION and jointly owned by both Parties if jointly invented by LIXTE and INSTITUTION;
provided, however, that INSTITUTION hereby grants to LIXTE a limited, non-exclusive, non-transferable and non-sublicensable license
to use any such INVENTIONS. Without limiting the foregoing and upon notice to the INSTITUTION, LIXTE may elect to receive an exclusive
license under such InventionS on the terms set forth in the Exclusive License Agreement
between INSTITUTION and LIXTE, dated as of the Effective Date (the “Exclusive License Agreement”). Upon such election,
such INVENTION is deemed to be Licensed Patent or Licensed
Information, as the case may be, under the Exclusive License Agreement. Patent Application 62/287,858 entitled “Clinical
Regimen for Treating Myelodysplastic Syndrome with Phosphatase Inhibitor”, filed by the parties with the United States Patent
and Trademark Office prior to the date of this AGREEMENT, is a Licensed Patent
under the Exclusive License Agreement and rights to such patent shall be governed by the provisions set forth in the Exclusive
License Agreement and not by the terms of this AGREEMENT.

 

14.
Notice

 

Whenever
any notice is to be given hereunder, it shall be in writing and mailed postage prepaid by certified or registered mail, return
receipt requested, or personally delivered to the appropriate party at the address indicated below, or via electronic delivery
or reputable overnight service with written verification of receipt at such other place or places as either party may designate
in a written notice to the other:

 

	To
    INSTITUTION:	H.
    Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
	 	Attn:
    Brian Springer, Vice President Research
	 	12902
    Magnolia Drive
	 	Tampa,
    Florida 33612

 

    	14

    	 

    

 

	with
    courtesy copy to:	 
	 	 
	 	H.
    Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
	 	Attn:
    Office of General Counsel
	 	Mailstop:
    SRB-OGC
	 	12902
    Magnolia Drive
	 	Tampa,
    Florida 33612-9497
	 	 
	and	 
	 	 
	 	H.
    Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
	 	Attn:
    Director, Clinical Trial Business Office
	 	Mailstop:
    MBC OCTBC
	 	12902
    Magnolia Drive
	 	Tampa,
    FL 33612-9497

 

	To
    PRINCIPAL INVESTIGATOR:	H.
Lee Moffitt Cancer Center and Research Institute Hospital, Inc.
	 	12902
    Magnolia Drive
	 	FOB
    3rd 5.3117
	 	Tampa,
    FL 33612-9497
	 	Attn.:
    Rami Komrokji, MD

 

	To
    LIXTE:	Lixte
    Biotechnology Holdings Inc.
	 	248
    Route 25A No. 2
	 	East
    Setauket, NY 11733
	 	Attn.:
    John S Kovach, MD

 

Notice
shall be deemed to have been received at the earlier of receipt or five (5) days from the date of mailing (in the case of a letter).

 

15.
Transfer and Use of SAMPLES

 

A.
“SAMPLES” shall mean, without limitation, blood, serum, fluid and tissue biopsy samples collected from subjects enrolled
in the STUDY. SAMPLES further include, without limitation, any tangible material directly or indirectly derived from such blood,
fluid or tissue samples, such as: genes, gene fragments, gene sequences, proteins, protein fragments, protein sequences, DNA,
and/or RNA. As between the Parties, INSTITUTION shall be the owner of SAMPLES provided by INSTITUTION to LIXTE in accordance with
this Section 15.

 

    	15

    	 

    

 

B.
LIXTE may receive pre-determined quantities of SAMPLES from INSTITUTION, as set forth in the Protocol, for use in research as
described in the Protocol or research as otherwise approved by an IRB, provided that such research complies with all applicable
laws and regulations, including, but not limited to those of HIPAA, NIH, FDA, and/or DHHS Federal Code of Regulations for the
protection of human subjects (45 CFR § 46.102).

 

C.
LIXTE shall in no way attempt to identify or contact the patients associated with the specimen(s) that make up the SAMPLES. Furthermore,
LIXTE shall not attempt to obtain or otherwise acquire any additional patient identifiable information associated with the SAMPLES
without the prior written consent of the INSTITUTION.

 

D.
LIXTE acknowledges and accepts that LIXTE shall be responsible for all reasonable costs and expenses associated with the transportation
of SAMPLES supplied by INSTITUTION to LIXTE, and LIXTE shall comply with all laws, regulations and requirements that apply to
shipping SAMPLES.

 

E.
Upon termination or expiration of the STUDY, whichever occurs first, the rights granted to LIXTE to receive and use the SAMPLES
shall terminate immediately unless (i) the Protocol or other IRB-approved research has provision for continued analysis or re-analysis
of the SAMPLES extending beyond the term of the STUDY up to a period of ten (10) years, or (ii) a separate agreement is in place
between INSTITUTION and LIXTE, which agreement shall be at least as restrictive as this AGREEMENT with respect to SAMPLES.

 

F.
The SAMPLES are provided AS IS without WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, AS TO ANY MATTER INCLUDING, BUT NOT
LIMITED TO, ACCURACY, RELIABILITY, COMPLETENESS, WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, EXCLUSIVITY, RESULTS
OBTAINED FROM USE, OR FREEDOM FROM PATENT, TRADEMARK, OR COPYRIGHT INFRINGEMENT.

 

G.
LIXTE acknowledges that the SAMPLES being supplied may have unknown characteristics and may carry infectious agents. All personnel
handling the SAMPLES shall be properly trained. LIXTE warrants that it has the knowledge and ability to safely handle any SAMPLES
supplied to it and agrees to use prudence and care in the handling, storage, transportation and containment of the SAMPLES. All
costs and expenses associated with such protective measures shall be borne by LIXTE. LIXTE shall be permitted to use an outside
laboratory for carrying out studies with the SAMPLES described herein provided LIXTE has an agreement in place between LIXTE and
outside laboratory at least as restrictive as this AGREEMENT with respect to the SAMPLES.

 

H.
The obligations of the parties under this Section 15 shall survive the termination or expiration of this AGREEMENT.

 

    	16

    	 

    

 

16.
Assignment

 

This
AGREEMENT is not assignable by INSTITUTION and any attempted assignment or delegation in violation hereof shall be void. Notwithstanding
the foregoing, INSTITUTION shall have the right to assign or delegate this AGREEMENT to one of its affiliates, subject to LIXTE’s
written consent, such consent not to be unreasonably withheld or delayed. This Agreement, including the indemnification provisions,
shall be binding upon and inure to the benefit of the parties hereto, their respective permitted successors, assigns, legal representatives
and heirs.

 

17.
Dispute Resolution

 

In
the event of any bona fide disagreement or disputed claim of any kind or nature between the Parties arising out of or relating
to this AGREEMENT or the breach, termination, enforcement, interpretation or validity
thereof, the rights or obligations of the parties hereunder, or any payments due hereunder (each, a “DISPUTE”), the
parties shall attempt in good faith to resolve any DISPUTE promptly by negotiation between executives who have authority to settle
the controversy and who are at a higher level of management than the persons with direct responsibility for administration of
this AGREEMENT. Upon the occurrence of a DISPUTE, a disputing Party shall notify
the other Party in writing of such DISPUTE (a “DISPUTE NOTICE”). The DISPUTE NOTICE shall include a statement of the
Party’s position and a summary of arguments supporting that position, together with information reasonably necessary for
the other Party to assess and respond to the subject of the DISPUTE, including copies of available supporting documents. Promptly
following such DISPUTE NOTICE, the executives of both parties shall meet at a mutually acceptable time and place in good faith
to attempt to resolve such DISPUTE by mutual agreement. If the DISPUTE has not been so resolved within thirty (30) days of the
DISPUTE NOTICE, either Party may seek equitable and legal remedies under the court system.

 

18.
Publicity

 

Neither
party shall use the name of the other party (or the name of any of LIXTE’s divisions or affiliated companies) for promotional
purposes without the prior written consent of the party whose name is proposed to be used; provided that, each Party acknowledges
that its name, the title of the Protocol and the total funded amount may be disclosed by the other Party to comply with reporting
obligations and applicable law. No news release, publicity or other public announcement, either written or oral, regarding this
AGREEMENT or performance hereunder or regarding results arising from the STUDY, shall be made by INSTITUTION without the prior
written approval of LIXTE.

 

19.
AGREEMENT Modifications

 

This
AGREEMENT may not be altered, amended or modified except by written document signed by both parties.

 

20.
Severability

 

If
any term or condition of this AGREEMENT, the deletion of which would not adversely affect the receipt of any material benefit
by either party hereunder, shall be held illegal, invalid or unenforceable, the remaining terms and conditions of this AGREEMENT
shall not be affected thereby and such terms and conditions shall be valid and enforceable to the fullest extent permitted by
law.

 

    	17

    	 

    

 

21.
No Waiver

 

Failure
on the part of LIXTE or INSTITUTION to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver
of any such right nor operate to bar the exercise or enforcement thereof at any time or times thereafter.

 

22.
Force Majeure

 

Noncompliance
by either party with the obligations of this AGREEMENT due to force majeure, (laws or regulations of any government, war,
civil commotion, destruction of production facilities and materials, fire, flood, earthquake or storm, labor disturbances, shortage
of materials, failure of public utilities or common carriers), or any other causes beyond the reasonable control of the applicable
party, shall not constitute breach of this AGREEMENT and such party shall be excused from performance hereunder to the extent
and for the duration of such prevention, provided it first notifies the other party in writing of such prevention and that it
uses reasonable efforts to cause the event of the force majeure to terminate, be cured or otherwise ended.

 

23.
Entire Understanding

 

This
AGREEMENT, including the Protocol, constitutes the entire agreement and sets forth the understanding between the parties herein,
and cannot be changed or amended except by written agreement executed by the parties. In the event of any inconsistency in this
AGREEMENT, the inconsistency shall be resolved by giving precedence first, to the Articles of this AGREEMENT, and then, to the
Protocol. The Parties agree that this AGREEMENT may be executed and delivered by facsimile, electronic mail, internet, or any
other suitable electronic means, and the Parties agree that signatures delivered by any of the aforementioned means shall be deemed
to be original, valid, and binding upon the Parties.

 

[REMAINDER
OF PAGE BLANK; SIGNATURE PAGE IMMEDIATELY FOLLOWS]

 

    	18

    	 

    

 

IN
WITNESS WHEREOF, the parties have caused this AGREEMENT to be executed, by duly authorized representatives, as of the last date
written below.

 

	H.
    Lee Moffitt Cancer Center and Research Institute Hospital, Inc.	 	Lixte
    Biotechnology Holdings, Inc.
	 	 	 	 	 
	BY:	 	 	BY:	 
	 	 	 	 	 
	NAME: 
    	John
    Musser	 	NAME: 	John
    S. Kovach, MD
	 	 	 	 	 
	TITLE:
    	Director,
    Clinical Trial Business Office	 	TITLE:
    	President
    & CEO
	 	 	 	 	 
	DATE:
    	 	 	DATE:	 
	 	 	 	 	 
	AGREED
    AND ACCEPTED:	 	 	 
	 	 	 	 	 
	BY:	 	 	 	 
	 	 	 	 	 
	NAME:
    	Rami
    Komrokji	 	 	 
	 	 	 	 	 
	TITLE:
    	PRINCIPAL
    INVESTIGATOR	 	 	 
	 	 	 	 	 
	DATE:
    	 	 	 	 

 

    	19

    	 

    

 

EXHIBIT
A

 

A
Ph1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic
Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy.

 

The
PROTOCOL is to be attached hereto and made a part hereof.

 

 

    	20

    	 

    

 

Table
of Contents

 

	1.	OBJECTIVES	9
	 	 	 
	2.	BACKGROUND	10
	 	 	 
	3.	STUDY
    ENDPOINTS	15
	 	 	 
	4.	INCLUSION
    / EXCLUSION CRITERIA	16
	 	 	 
	5.	STUDY
    DESIGN INCLUDING DLT INFORMATION	18
	 	 	 
	6.	TREATMENT PLAN	20
	 	 	 
	7.	DURATION
    OF THERAPY	22
	 	 	 
	8.	DURATION
    OF FOLLOW-UP 	22
	 	 	 
	9.	CRITERIA
    FOR REMOVAL FROM STUDY 	22
	 	 	 
	10.	DOSING
    DELAYS/MODIFICATIONS 	24
	 	 	 
	11.	ADVERSE
    EVENTS: REPORTING REQUIREMENTS	26
	 	 	 
	12.	PHARMACEUTICAL
    INFORMATION	33
	 	 	 
	13.	STUDY
    CALENDAR 	33
	 	 	 
	14.	MEASUREMENT
    OF EFFECT	38
	 	 	 
	15.	STATISTICAL
    CONSIDERATIONS	39
	 	 	 
	16.	PHARMACOKINETICS	43
	 	 	 
	17.	LABORATORY
    CORRELATES	43
	 	 	 
	18.	REGULATORY
    CONSIDERATIONS	45
	 	 	 
	19.	REFERENCES	49
	 	 	 
	20.	APPENDIX
    A: ECOG PERFORMANCE STATUS	50
	 	 	 
	21.	APPENDIX
    B: IWG 2006 RESPONSE CRITERIA	51
	 	 	 
	22.	APPENDIX
    C: IPSS	52
	 	 	 
	23.	APPENDIX
    D: WHO CLASSIFICATION OF MDS	53

 

    	21

    	 

    

 

Protocol
Synopsis

 

Title:
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic
Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy

 

	Study

                                                         
	Primary
                                         Objective (Phase1b):

	 
	Objectives	 	 
	 	1.
	To
    determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of LB-100 as determined by dose-limiting toxicities
    (DLTs)	 
	 	 	 	 
	 	Primary
                                         Objective (Phase 2):

	 
	 	 	 
	 	2.
    	To
                                         estimate overall best response rates of LB-100 using standard international working group
                                         (IWG) 2006 response criteria

        
	 
	 	 	 	 
	 	Secondary
    Objectives (Phase 1b and 2):

	 
	 	 	 
	 	3.
    	To
                                         characterize the plasma pharmacokinetics (PK) of LB-100 (Phase 1b only)

        
	 
	 	4.
    	To
                                         evaluate the effect of LB-100 on the hematologic and cytogenetic response in patients
                                         with deletion 5q (del(5q)) MDS

        
	 
	 	5.
    	To
                                         estimate the duration of response

        
	 
	 	6.
    	To
                                         estimate the time to AML transformation of subjects on LB-100

        
	 
	 	7.
    	To
                                         characterize in vivo LB-100 target inhibition

        
	 
	 	8.
    	To
                                         characterize the effect of LB-100 treatment on erythropoietin signaling

        
	 
	 	9.
    	To
    determine whether recurrent genetic mutations are predictive of LB-100 response	 
	 	 	 	 

	Study
    Endpoints	Primary	

 	 
	 	 	1.	Phase
    1b: In the first 2 cycles, the occurrence of DLTs, as defined below, graded according to the National Cancer Institute Common
    Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.	 
	 	 	2.	Phase
                                         2: Achievement of hematological improvement (HI) and/or cytogenetic response by the IWG
                                         2006 criteria (see appendix B). Patients who achieve such a response will be categorized
                                         as “responders” and the rest of the patients will be categorized as non-responders.

        
	 
	 	Secondary	

	 
	 	 	3.	Plasma
                                         concentrations within Phase 1b patient cohort only

        
	 
	 	 	4.	The
                                         response of MDS patients with del(5q) who achieve HI and/or cytogenetic response.

        
	 
	 	 	5.	Duration
                                         of response defined as the time from achievement of HI, PR, CR, mCR until progression
                                         of disease or death due to disease.

        
	 
	 	 	6.	Acute
                                         myeloid leukemia (AML) transformation according to World Health Organization (WHO) criteria
                                         (see Appendix B).

        
	 
	 	 	7.	PP2A
                                         activity measured via Active PP2A assay kit in peripheral blood before and after LB-100
                                         administration and assess downstream target inhibition in phosphorylation of PP2A substrates
                                         (e.g. CDC25C, MDM2, AKT) and p53 expression by immunohistochemistry (IHC) in bone marrow
                                         (BM) samples.

        
	 
	 	 	8.

        
	Erythropoietin-induced
    STAT5 activation in erythroid progenitors as measured by flow cytometry.	 
	 	 	9.
    	Determine
                                         recurrent gene mutations in ABL1, ASXL1, CBL, CEBPA, CSF3R, CUX1, DNMT3A, ETV6,
                                         EZH2, FLT3, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MLL, MPL, MYD88, NPM1, NRAS, PHF6, RUNX1,
                                         SETBP1, SF3B1, SH2B3, SRSF2, TET2, TP53, U2AF1, WT1, and
                                         ZRSR2 at study entry and end of treatment.
	 
	 	 	 	 	 

 

    	22

    	 

    

 

[***]

 

    	23

    	 

    

 

EXHIBIT
B

 

BUDGET
AND PAYMENT TERMS

 

	Sponsor:	 	Lixte
    Biotechnology Holdings, Inc.
	Protocol
    TITLE:	 	A
    Ph1b/2 Study Evaluating the Safety and Efficacy of Intravenous LB-100 in Patients with Low or Intermediate-1 Risk Myelodysplastic
    Syndromes (MDS) who had Disease Progression or are Intolerant to Prior Therapy

 

[***]

 

    	24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]